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Background: Over the past 20 years or so, the drug misuse scenario has seen the
emergence of both prescription-only and over-the-counter (OTC) medications being
reported as ingested for recreational purposes. OTC drugs such as antihistamines,
cough/cold medications, and decongestants are reportedly the most popular in being
diverted and misused.
Objective: While the current related knowledge is limited, the aim here was to
examine the published clinical data on OTC misuse, focusing on antihistamines
(e.g., diphenhydramine, promethazine, chlorpheniramine, and dimenhydrinate),
dextromethorphan (DXM)- and codeine-based cough medicines, and the nasal
decongestant pseudoephedrine.
Methods: A systematic literature review was carried out with the help of Scopus,
Web of Science databases, and the related gray literature. For data gathering
purposes, both the Preferred Reporting Items for Systematic Reviews andMeta-analyses
(PRISMA) and PROSPERO guidelines were followed (PROSPERO identification
code CRD42020209261).
Results: After completion of the selection, eligibility, and screening phases, some 92
articles were here taken into consideration; case reports, surveys, and retrospective case
series analyses were included. Findings were organized according to the specific OTC
recorded. Most articles focused here on DXM (n = 54) and diphenhydramine (n = 12).
When specified, dosages, route(s) of administration, toxicity symptoms (including both
physical and psychiatric ones), and outcomes were here reported.
Conclusion: Results from the systematic review showed that the OTC misusing issues
are both widespread worldwide and popular; vulnerable categories include adolescents
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and young adults, although real prevalence figures remain unknown, due to a lack of
appropriate monitoring systems. Considering the potential, and at times serious, adverse
effects associated with OTCmisusing issues, healthcare professionals should be vigilant,
and ad hoc preventative actions should be designed and implemented.
Keywords: drug abuse, drug misuse, prescription drug misuse, pharming, drug diversion, over the counter drug
misuse, addiction, OTC
INTRODUCTION
Since generally being considered safe, over-the-counter (OTC)
medicines are available without a prescription and can be
purchased directly from related pharmacies/stores (1, 2). OTC
medicines are meant to treat a variety of illnesses and symptoms,
including pain, coughs and colds, diarrhea, nausea, etc. OTC
availability, while encouraging self-care, has contributed to a
public perception of safety and a lack of awareness relating
to their potential for misuse, dependence, and harm (3–6).
Indeed, some OTC medicines have active ingredients possessing
a misusing potential at higher-than-recommended dosages (7)
and are becoming increasingly popular for the possibility of their
diversion in order to reach central psychoactive effects (8–11).
Currently, there is minimal information about the prevalence of
OTC misuse, abuse, and dependence (8–10, 12). Indeed, current
lack of knowledge may partly be due to poor sales’ monitoring
because of OTCs’ favorable legal status. However, the so-called
“pharming” phenomenon (13–15) has been requiring attention
at different levels because of increased treatment admissions,
dangerous behavior, more emergency room visits, drug-related
deaths, and overdoses (11, 16, 17). Most implicated drugs include
certain cough suppressants, sleep aids, and antihistamines,
which can at times be ingested in combination with remaining
recreational psychotropics and/or prescription drugs and/or
alcohol (17, 18). Overall, the misuse of OTC drugs is considered
as more socially acceptable, less stigmatizing, and safer than
the intake of illicit substances, also due to their likely lack of
detection in standard drug screens (16). OTC drugs’ intake
may involve snorting or injecting the crushed tablets’ powder
to amplify the effects of a drug or ingesting these molecules
for a purpose different from the therapeutic one. This may
be the case for dextromethorphan (DXM) and codeine-based
cough mixtures, being possibly misused at high dosages for
recreational or euphoric effects; conversely, loperamide is at
times being ingested for self-medicating withdrawal symptoms
(7, 16, 18–20). OTC misuse has also been associated with notable
drug interactions, physical and mental health effects, individual
variation in responses, and significant socioeconomic impact
for the users, their family, and the wider community (13–15).
Currently, most OTCmisusing data are obtained through clinical
records (e.g., case reports and case series) and surveys.
Aims of the Study
Thus, the current review aimed at (i) examining the current
literature on the misuse of OTC drugs, focusing on the following
OTCs: among antihistamines, diphenhydramine (DPH),
promethazine, chlorpheniramine, and dimenhydrinate (DH);
DXM- and codeine-based cough medicines; and the nasal
decongestant pseudoephedrine; (ii) illustrating patterns of
OTCs’ misuse, psychopathological effects, and harms associated;
and (iii) better understanding the psychotropic molecular
mechanisms underlying their recreational use.
METHODS
Systematic Review Procedures
A systematic electronic search was conducted from October
2020 to December 2020 and was set without a timeframe on
the following scientific search engines: PubMed, Scopus, and
Web of Science (WoS). The gray literature was also checked
for relevant information. The following search strategies
were used, respectively, in PubMed: (“diphenhydramine” OR
“promethazine” OR “chlorpheniramine” OR “dimenhydrinate”
OR “dextromethorphan” OR “pseudoephedrine” OR codeine-
based cough medicines) AND (“abuse” OR “misuse” OR
“craving” OR “addiction”) NOT review NOT (animal
OR rat OR mouse) NOT “in vitro;” in Scopus: [TITLE-
ABS-KEY (“Diphenhydramine”) OR TITLE-ABS-KEY
(“Promethazine”) OR TITLE-ABS-KEY (“Chlorpheniramine“)
OR TITLE-ABS-KEY (“Dimenhydrinate”) OR TITLE-
ABS-KEY (“Dextromethorphan”) OR TITLE-ABS-KEY
(“Pseudoephedrine”) OR TITLE-ABS-KEY (codeine-based
cough medicines) AND TITLE-ABS-KEY (“Abuse”) OR TITLE-
ABS-KEY (“Misuse”) OR TITLE-ABS-KEY (“Craving”) OR
TITLE-ABS-KEY (“Addiction”) AND NOT TITLE-ABS-KEY
(Review) ANDNOTTITLE-ABS-KEY (animal) ORTITLE-ABS-
KEY (rat) OR TITLE-ABS-KEY (mouse) AND NOT TITLE-
ABS-KEY (“in vitro”)]; and WoS: (“diphenhydramine” OR
“promethazine” OR “chlorpheniramine” OR “dimenhydrinate”
OR “dextromethorphan” OR “pseudoephedrine” OR codeine-
based cough medicines) AND (“abuse” OR “misuse” OR
“craving” OR “addiction”) NOT Review NOT (animal OR
rat OR mouse) NOT “in vitro.” The systematic review
was structured in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
(21) and PROSPERO guidelines (22). All data collected
were tabulated on an Excel sheet to enable easy comparison
and analysis.
Data Synthesis Strategy
The selection and eligibility phase of the articles was carried
out by three independent reviewers (AM, AMo, and MCS),
who screened articles based on title and abstract; the first
screening was followed by full text reviews, using predetermined
criteria for inclusion and exclusion. Eligible articles were
Frontiers in Psychiatry | www.frontiersin.org 2 May 2021 | Volume 12 | Article 657397
Schifano et al. Focus on Over-the-Counter Drugs’ Misuse
considered if the published studies met all the following
criteria: (i) original articles (open-label or double-blind trials,
prospective or retrospective observational studies, case series
and case reports); (ii) studies involving all age individuals
misusing the OTC drugs selected. There were no other
restrictions on the type of study population or publication
time period. Exclusion criteria were as follows: (i) nonoriginal
research articles (e.g., review, letter, commentary, editorial,
book chapter, professional or clients’ opinions); (ii) non full-
text articles (e.g., meeting/conference abstracts); (iii) languages
other than English; (iv) animal/in vitro studies; (v) articles
mentioning OTC drugs only as an example in the context
of OTC drugs misuse; and (vi) articles not dealing with the
misuse of the OTC drugs selected (e.g., DPH, promethazine,
chlorpheniramine, and DH; DXM- and codeine-based cough
medicines; and pseudoephedrine). Individual studies were also
manually searched to identify additional citations. A final,
between reviewers, cross-check was carried out, supervised
by SC and MP, with both doubtful cases and possible
inclusion/exclusion disagreements resolved through discussion
with GM, MDG, and FS.
Protocol and Registration
Current research methods were approved by PROSPERO
(identification code CRD42020209261).
FIGURE 1 | PRISMA flow diagram.
Frontiers in Psychiatry | www.frontiersin.org 3 May 2021 | Volume 12 | Article 657397
Schifano et al. Focus on Over-the-Counter Drugs’ Misuse
Risk of Bias
The assessment of risk of bias was made in accordance with the
Cochrane risk of bias 2 (RoB 2) tool (23).
RESULTS
In removing duplicate articles (n = 566) from a total of 2,136
papers (PubMed = 393; Scopus = 1,372; WoS = 362; additional
sources = 9), some 15,70 records resulted to be relevant for
screening. Those considered not relevant to the subject while
considering both the title and the abstract (n = 1,103; e.g.,
animal/in vitro studies; articles only mentioning OTC drugs,
or not regarding OTC misuse/abuse, or not giving a clear
description of related symptoms), those not written in English (n
= 136), and those that were non-original articles (n = 87) were
eliminated. Out of the 244 remaining full-text articles assessed
for eligibility, some 125 papers did not match the inclusion
criteria and 27 were not available. Hence, 92 articles were taken
into consideration and properly analyzed (Figure 1). Findings
were organized according to the specific OTC recorded, reported
in alphabetical order in Supplementary Table 1; conversely, the
most relevant characteristics of the misusing potential of the
range of OTC drugs commented are summarized in Table 1.
Dextrometorphan
DXM resulted to be the most reported misused drug,
with n = 54 related papers having been here identified
(Supplementary Table 1). Indeed, it was recorded in two
retrospective studies (24, 25), in 10 case series (26–35), and in
several case reports (24, 25, 36–77). Most represented users were
male adolescent and young adults; DXM was mostly used alone
(28, 36, 37, 40, 44, 45, 54, 57, 66) or in DXM-containing cough
mixtures (26, 29, 30, 39, 41, 42, 47, 50, 52, 53, 62, 64, 68, 71, 72, 74,
76). Concomitant drugs included both licit and illicit substances,
such as alcohol (25, 30, 31, 35, 52, 53, 55, 60, 71, 76); cannabis
(25, 31, 35, 48, 60); sedatives drugs, e.g., benzodiazepines
(35); diethylamide lysergic acid (LSD) (35); opioids, e.g.,
morphine, heroin (25, 35, 54); ecstasy (35); cocaine (35); and
phencyclidine/ketamine (34, 35). Dosages varied among cases,
up to super-high dosages (up to 4,920mg) (31, 35, 36, 61).
The only route of administration (ROA) here recorded was the
oral one. Autonomic (e.g., mydriasis, tachycardia, palpitations)
(30, 33, 35, 42, 44, 46, 47, 51, 67, 70, 71), gastrointestinal
(32, 35, 42, 47), neurological [e.g., amnesia, nystagmus, ataxia,
seizures, and dystonia; (24, 26, 29, 30, 32, 34, 35, 39, 43–
46, 49, 51–53, 56, 59, 67)], and psychiatric symptoms, such as
euphoria, agitation/irritability, confusion, hallucinations, and
delusions, have been recorded (24, 25, 27–31, 33–38, 40–
50, 52–54, 56, 58, 60, 61, 63, 66, 67, 70–74, 76). DXM
misusers’ psychiatric history frequently included alcohol
and substance use disorders (SUD) (25–27, 29, 31, 32, 34–
37, 40, 43, 45–48, 50, 53, 55–62, 64–67, 69, 76), mood
disorders (29, 31, 32, 35, 37, 38, 41, 46, 56–65, 67, 68, 71),
and schizophrenia (37, 53, 69). Regarding the outcome, most
cases required hospitalization with supportive treatments and
antipsychotics [e.g., haloperidol (43, 47, 71, 73, 75)], risperidone
(74), and olanzapine (54, 61) administration. A DXM-related
suicide has been recorded (31).
Chlorpheniramine and Codeine
Chlorpheniramine and codeine were recorded as having been
misused in two papers (respectively, 68 and 69), as constituents
of BRON, a Japanese codeine-based cough suppressant, together
with methyl-ephedrine and caffeine (78, 79). BRON abuse has
been associated with both psychotic/affective symptoms and
dependence/withdrawal issues (78). Moreover, a case of severe
intoxication of a codeine-based cough mixture determining a
respiratory acidosis and requiring hospitalization was recorded
(80) (Supplementary Table 1).
Dimenhydrinate
DH misuse was described in eight articles
(Supplementary Table 1), including five case reports (81–
85) and three case series (86–88), mostly involving adults or
adolescents (88). Most important psychiatric comorbidities
described were represented by mood disorders (82, 84),
SUD (83–87), and schizophrenia (85, 87). Massive dosages,
up to 5,000mg, of DH have been recorded in a few cases
(84, 85, 87). DH administration was always oral, except for
one case where the molecule was administered intramuscularly
in association with opiates and benzodiazepines (83). The
symptoms recorded ranged from recreational stimulating
effects (87) to emotional lability, agitation, anxiety, and drug-
induced delirium with paranoia, thought incoherence, and
visual/auditory hallucinations (81, 86). The physical effects
reported were mild and included mydriasis, tachycardia,
hypertension, flushing, restlessness, dystonic reactions, and
ataxia (81, 82, 84–86, 88), while one case reported generalized
seizures (87). Withdrawal symptoms have been recorded after
the abrupt interruption of chronic use and included irritability,
anxiety, and craving (82, 84, 87). When reported, treatment was
almost supportive (81–83, 85, 88); in two cases, benztropine
was required to treat dyskinesia and related movement, muscle
control, and balance symptoms (81, 84).
Diphenhydramine
DPH misuse was reported in 12 articles, including 10 case
reports (17, 89–97); the remaining two included, respectively,
a case series (98) and a retrospective review study (99)
(Supplementary Table 1). Apart from the retrospective review
study focusing on all Mandrax R© (DPH + Methaqualone)
abuse cases (n = 67, male) retrieved from the United States
(US) Army during January–June 1972, users were here mostly
represented by female (F/M, 9/6). A high number of users
were adolescents, aged between 13 and 18 years (17, 94, 96–
98). Reported psychiatric comorbidities mostly included
SUD (17, 89–92, 95), schizophrenia/psychotic symptoms
(89, 91, 92), and mood disorders (17, 90, 91). DPH was
taken in most cases orally, but both intramuscular (IM) (90)
and intravenous (IV) (96–98) administrations were reported
as well. Super-high dosages were recorded, up to 2,000mg
daily (91–93, 98). In a few cases, DPH was misused together
with alcohol (91, 99), lorazepam (98), and cannabis (99).












































Oral • Chlorpheniramine acts primarily as
a potent H1 antihistamine drug
• Moderate anticholinergic activity
• Chlorpheniramine has been found
to act as a serotonin
reuptake inhibitor
• ACUTE EFFECTS: psychiatric effects: (i) sedating
and anxiolytic properties; (ii) its abuse has been
related to pleasurable feelings such as euphoria
and stimulating effects; (iii) it may be associated
with psychotic symptoms in predisposed
individuals (e.g., people with mental illnesses or
individuals concomitantly abusing other drugs)
• CHRONIC EFFECTS: dependence
• Drug dependence is recorded after
long-term use




“Triple c” refers to Coricidin®
cough and cold tablets; the
combination of codeine, methyl
ephedrine chlorpheniramine, and
caffeine is marketed as Bron®;








Codeine (opioid) Oral, IV • It is a selective agonist of the
mu-opioid receptor; it is a natural
isomer of methylated morphine,
requiring metabolic activation by
O-demethylation to morphine
by CYP2D6
• ACUTE EFFECTS: psychiatric effects: euphoria,
elation, analgesia, calmness; physical effects:
respiratory depression, extreme somnolence
progressing to stupor or coma, skeletal muscle
flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. The triad of coma,
pinpoint pupils, and respiratory depression is
strongly suggestive of opiate poisoning. In severe
overdosage, death may occur
• CHRONIC EFFECTS: dependence
• Codeine has an identified abuse
liability potential, given its effect and
development of tolerance within a
short timeframe on regular or
excessive use
• Codeine-dependence was here
recorded, and associated with daily
use of codeine
Street names: “Captain Cody,”
“Cody,” “Little C,” “Schoolboy,”
“Doors & Fours.” Common
brand names for codeine and
codeine containing
combinations: Aspalgin® for
aspirin and codeine; Nurofen














• At high doses, acting as a NMDA
receptor antagonist, DXM and its
potent metabolite dextrorphan




• DXM also exhibits binding activity
at serotonergic receptors
• Neurobehavioural effects begin within 30–60min
of ingestion and persist for approximately 6 h
• They are dose-related, starting from a mild to
moderate stimulation with restlessness and
euphoria (100–200mg), to a state characterized
by hallucinations, paranoia, perceptual
distortions, delusional beliefs, ataxia, and
out-of-body experiences (>1,000mg)
• ACUTE EFFECTS: (i) psychiatric effects: euphoria,
altered mental status, mania, mood lability,
irritability, dysphoria, insomnia; (ii) physical effects:
tachycardia, hypertension, vomiting, mydriasis,
diaphoresis, nystagmus, dystonia, loss of motor
coordination;
• CHRONIC EFFECTS: (i) toxic psychosis and
cognitive deterioration; (ii) folate deficiency and
neuropathy; (iii) since DXM is produced as the
crystalline hydrobromide salt, bromism is a rare
consequence that has been identified in heavy
chronic abusers of DXM (neurotoxic effects,
resulting in somnolence, psychosis, seizures,
and delirium
• Although DXM is not thought to
have addictive properties, its







• EMCDDA: regarded as NPS
Street names: “Bromage,”
“Brome,” “Candy,” “Dex,”
“Dextro,” “DM,” “Drex,” “DXM,”
“Red Devils,” “Robo,” “Rojo,”
“Skittles,” “Triple C,” “Tussin,”
“Velvet,” and “Vitamin D,” “Poor
Man’s Ecstasy”; the practice of
using large amounts of DXM to
achieve psychoactive effects is
known as “robotrippin.”
Common brand names are:
Balminil DM®, Benylin DM®,
Bronchophan®, Buckleys D®,




































































































• It is a first generation
H1-antihistamine
• Diphenhydramine also acts as a
potent anticholinergic agent
• It can acutely block the cell
membrane pump mechanism of
central 5-hydroxytryptophane and
peripheral noradrenaline neurons
• ACUTE EFFECTS: (i) psychiatric effects: euphoria,
altered mental status, hallucinations, and/or
psychosis; (ii) physical effects: tachycardia,
xerostomia, mydriasis, blurred vision, ileus,
urinary retention, CNS depression, agitation, and
hyperactivity
• CHRONIC EFFECTS: dependence
• Reported cases of DPH
dependence have resulted from
usage of large doses (often over
1,000mg per day) over periods of
months or years. Withdrawal
symptoms include craving,
worsening of insomnia, rhinorrhoea,
nausea, irritability, restlessness,
abdominal cramps, sweating, and
diarrhea. Gradual tapering has
been the only described
detoxification treatment plan






Oral • It is a phenothiazine derivative and
a H1 receptor antagonist; It also
acts as a direct antagonist at
muscarinic (M1) and dopamine (D2)
receptors. It is classified as a
first-generation antihistamine
molecule which easily penetrates
the blood-brain barrier and is
associated with adverse effects
such as sedation
• ACUTE EFFECTS: from mild sedation and CNS
depression to profound hypotension, respiratory
depression, unconsciousness, and sudden
death; overdosage might determine an
antimuscarinic delirium, agitation and neuroleptic
malignant syndrome
• it can be used to enhance effects of other
co-ingested substances, e.g., opioids
• CHRONIC EFFECTS: NR
• EMCDDA: regarded as NPS
• Dependence might develop after
long-term use of promethazine
cough mixtures (containing opioids)
Promethazine mixed with a soft
drink and/or alcohol is known as
“purple drank,” “lean,” “syzzurp,”
“Texas tea”; Phenergan® and









exerting a stimulating action on
alpha, beta1-, and
beta2-adrenergic receptors
• ACUTE EFFECTS: stimulant effects, e.g.,
euphoria, insomnia, diminished sense of fatigue,
anorexia, and accelerated thinking; psychotic
symptoms with auditory and visual hallucinations,
persecutory delusions, fear, disorganized behavior
might develop after high-dose consumption
• CHRONIC EFFECTS: dependence
• Dependence might be developed
after long-term use
• Withdrawal symptoms include:
dysphoria, restlessness, abnormal
perceptions
• Due to the possibility to be used to
manufacture the class A controlled
drug methylamphetamine,
restrictions have been in place in
the UK to manage the risk of
products containing
pseudoephedrine and ephedrine; in
the US, a prescription is not
needed in most States, and in
remaining States there are limits on







acetylsalicylic acid diluted in




CNS, central nervous system; DH, Dimenhydrinate; DPH, Diphenhydramine; EMCDDA, European Monitoring Centre for Drugs and Drug Addiction; GABA, Gamma-Amino-Butyric Acid; H, Histamine; IN, Intranasal; IV, Intravenous;
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A polydrug overdose (e.g., DH together with bupropion,
citalopram, acetaminophen, omeprazole, and naproxen) was
recorded (94). DPH recreational use was associated with
relaxation, calmness, and sleep improvement (90, 92, 96, 98, 99).
Acute intoxication was associated with psychotic symptoms,
psychomotor agitation, restlessness, and disorientation (89, 92–
96, 98, 99). Withdrawal, consisting in both physical (e.g.,
bowel and bladder incontinence, hypertension, hypertonia, and
extrapyramidal symptoms) and psychological (e.g., anxiety,
irritability, rebound insomnia, and craving) symptoms have been
recorded (17, 89, 90, 92, 95, 98, 99). DPH-induced intoxication
was associated with signs and symptoms of anticholinergic
toxicity, such as fever, mydriasis, flushed skin, dry mouth, dry
eyes, decreased sweating, urinary retention, and dyskinesia
(92–94, 98). A severe toxicity case was associated with cardiac
conduction abnormalities and increased QT interval (90).
On-drug cases of violent behavior, including suicide, have
been reported (97, 99). Treatment required hospitalization
and supportive care; drugs used were antipsychotics,
such as fluphenazine and quetiapine, benzodiazepines,
and benztropine (89, 90, 92, 93).
Promethazine
A few papers recorded here the misuse of promethazine; a
retrospective analysis of data from the American Association
of Poison Control Centres (AAPCC) National Poison Data
System (NPDS) from January 2002 to December 2012 reported
354 promethazine intentional misuse/abuse cases (100)
(Supplementary Table 1). All cases involved adolescents and
young adults who misused promethazine orally. In most
cases (n = 259) promethazine abuse was associated with
other substances, such as DXM, codeine, phenylephrine,
pseudoephedrine, caffeine, etc. Intoxication symptoms ranged
from mild to severe effects, up to seizures and coma, but no
fatalities have been reported. Agitation, confusion, slurred
speech, and hallucinations were described as well. Promethazine-
alone abuse cases were mostly managed in healthcare facilities,
while promethazine in coformulationmostly required emergency
department (ED) care management (100). Moreover, further
cases of nonmedical use of promethazine were here identified
from (i) the Danish Poison and Information Centre (DPIC)
and related registers used within the State Serum Institute
of Denmark (SSI) (101); (ii) a prospective database of
poisoning admissions (January 1987-May 2007) to a UK
regional toxicology service (102); and (iii) a prospective study
regarding patterns of misuse of heroin injectors (103). Drug-
induced delirium was the most represented psychiatric effects;
this was managed with antipsychotics and benzodiazepines
(101, 102). Interestingly, the use of promethazine injection
in opioid users was reported as a substitute for heroin
or to increase the effects of an inadequate heroin dosing
(103). A case of drug-induced delirium deriving from the
coingestion of high-dose promethazine, cyproheptadine, and
fluvoxamine in a young girl was recorded (104). Finally, a
case of promethazine dependence and withdrawal after 2-
year continuing use of a promethazine–cough mixture was
described (105).
Pseudoephedrine
Seven articles, including six case reports (106–111) and one
case series (112), described the misuse of pseudoephedrine
(Supplementary Table 1). Cases mostly involved male adults
(age range, 18–45 years) (F/M, 3/7) suffering from mood
disorders (107, 109–111). One paper recorded an SUD
[e.g., alcohol, cannabis, and heroin; (112)]. Massive dosages
[e.g., 3,000–4,500mg of pseudoephedrine/day; (107)] and
IV administrations (108, 111, 112) have been associated
with the misuse of pseudoephedrine. Physical symptoms
associated with pseudoephedrine high dosage ingestion included
stimulating effects such as decreased appetite, dry mouth,
palpitations (106, 107, 112), and motor symptoms [e.g., gait
and balance disorder, postural instability, generalized dystonia,
hypokinesia, bradykinesia, psychomotor retardation; (106–108,
112)]. Pseudoephedrine effects were dose dependent and ranged
from euphoria, insomnia, diminished sense of fatigue, and
accelerated thinking, to psychotic symptoms with auditory
and visual hallucinations, persecutory delusions, fear, and
disorganized behavior (106, 109–111). Withdrawal symptoms
have been recorded after the abrupt interruption of the long-
term use (106, 107). Some cases required hospitalization and
treatment with antipsychotics, e.g., haloperidol (106, 109–111);
benzodiazepines (108); and antidepressants, e.g., amitriptyline
(106, 108). No fatalities have been recorded.
DISCUSSION
This systematic review has illustrated a range of both themes
and data regarding the misuse/abuse of some selected OTC
drugs, including DXM, DPH, DH, codeine-based cough syrups,
promethazine, and pseudoephedrine. Their misuse potential may
be particularly significant in adolescents and young adults (10,
12, 113). OTC recreational intake appeared to be associated
with high/very high dosages (17, 27, 30, 31, 35, 36, 40, 42, 45,
46, 55, 58, 61, 66, 76, 79, 84, 85, 88, 90–93, 104, 107, 114);
idiosyncratic routes of administration (e.g., snorting; IM; IV; 39,
69, 88–90, 100, 103); and associated with ingestion of both licit
[e.g., alcohol, prescription opioids, benzodiazepines, other OTCs;
(25, 35, 49, 52–55, 60, 61, 72, 76, 83, 91, 94, 99, 101, 102)] and
illicit (e.g., cannabis, cocaine, ketamine, etc.) drugs (30, 31, 34,
35, 48, 58, 60, 61, 88, 99). OTC drugs were obtained by various
means (8–11), including family and friends (63), multiple doctor
prescriptions (27, 36, 63, 90, 93), illegal online pharmacies/shops
(36, 42, 70, 77), and theft/burglary from hospitals, residences,
and pharmacies (27, 105, 110). DXM pills named “Snurf” were
also reported to have been acquired online and in having been
marketed as a legal high (70).
Overall, two main populations of OTC misusers were
identified (11): (a) patients already suffering from a health
condition and/or a psychiatric disorder who became dependent
on their prescription/OTC drugs due to prolonged/high-dosage
use (115), e.g., DXM-based cough mixtures started for sinusitis,
cough, nasal congestion, and then continued for years at
higher dosages (27, 58). Other examples have included DH
prescribed for emesis in pregnancy and then continued for
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12 years at a higher dosage without a prescription (82),
DPH use initiated to assist with initial insomnia and then
continued for 6 months up to 1,600mg daily (92), and
pseudoephedrine self-administered to lose weight then causing
addiction (106); (b) individuals, including substance abusers, not
in treatment for a medical disorder or illness who may have
started to misuse/abuse with OTC medications for recreational
purposes (36, 40, 43, 45, 70, 116).
Out of a total of n = 185 OTC misusers described in
case reports/series surveys (24, 25, 77, 78, 99–103), male
subjects were the most represented (F/M = 51/134), with an
SUD history having been recorded in 53 of them (53/185
= 28.6%). A range of psychiatric diagnoses were reported
(45/185 misusers, 24.3%), including mood disorders (e.g., bipolar
disorder, depression, dysthymia; N = 26), anxiety disorders (e.g.,
adjustment disorder, anxiety; N = 5), psychotic disorders (e.g.,
schizoaffective disorder, schizophrenia, psychosis, delusional
disorder; N = 11), attention deficit and hyperactivity disorder
(ADHD, N = 1), eating disorders (e.g., bulimia; N = 1),
and personality disorders (e.g., dependent disorder; N = 1).
Regarding the outcome, most cases recorded were associated
with a full recovery after hospitalization, with treatment having
been either supportive (32, 44–46, 65) or symptomatic, with the
latter consisting of benzodiazepines and antipsychotics (25, 27,
28, 43, 47, 49, 51, 54, 61, 67, 68, 71, 73–75, 79, 111, 115). A full
detoxification procedure was recorded in cases of dependence
and withdrawal (17, 82, 92, 95, 98, 105, 107, 109, 115); examples
included buprenorphine 2 mg/day to treat a sudden opiate
(codeine) withdrawal symptoms (114), naltrexone as a relapse
prevention agent for DXM dependence (63), and topiramate
for DXM craving (56). Some cases required specific actions
in the Emergency Unit (80). Finally, it has been suggested
here that drug use treatment would benefit from counseling,
behavioral therapies support, and rehabilitation treatment to
better overcome drug craving (11, 18, 27, 28, 34, 36, 46, 48, 53, 59,
60, 78, 84, 110, 117). OTC-related fatalities were here related to
either cases characterized by unusually high dosages (24, 31, 96)
or to suicide/self-aggression (31).
The cough-suppressant DXM resulted here to be the most
popular OTC being misused (Supplementary Table 1) due
to its dose-dependent sedative, dissociative, and stimulant
properties (16, 118–120). Indeed, DXM psychotropic effects
are mostly related to its active metabolite dextrorphan,
which, if used in large dosages, is able to antagonizes N-
methyl-D-aspartate (NMDA) receptors, hence modulating the
excitatory neurotransmission; this results in the production
of specific dissociative, ketamine-like, experiences (19, 25,
31, 56, 118–121) (Supplementary Table 1 and Table 1). The
effects depend upon several factors, such as an individual’s
CYP2D6 subtype, body weight, as well as the degree of
tolerance to DXM, and the concomitant use of other CYP2D6
substrates, including antidepressants (fluoxetine, fluvoxamine,
nefazodone, paroxetine, sertraline, venlafaxine), antipsychotics
(clozapine, haloperidol, risperidone, thioridazine), β-blockers
(atenolol, metoprolol, propranolol), antiarrhythmics, and opioid
analgesics (codeine, tramadol, and methadone), which may
decrease the rate of DXM metabolism, resulting in a DXM
intoxication (13, 19, 47, 121, 122). Due to DXM catabolism
by repeated demethylation, which may lead to abnormal folate
demands for methyl group transfer, a folate deficiency has been
described in association with chronic DXM use (26, 39, 122).
In addition, dental caries cases were associated with the high
syrup content of cough mixtures (26). Although DXM is not
thought to have addictive properties, with chronic use, vulnerable
individuals may rapidly develop tolerance, dependence, and
withdrawal (35, 36, 56, 58, 63, 66, 76). Interactions with
other substances can often produce synergistic effects; in fact,
OTC cough formulations frequently contain, in addition to
DXM, other pharmaceutical agents such as chlorpheniramine,
acetaminophen, or pseudoephedrine, exhibiting different effects.
Indeed, individuals abusing with chlorpheniramine-containing
DXM formulations may also exhibit anticholinergic signs and
symptoms (25, 31, 42, 47, 49, 73, 74, 123). Conversely, the
antipyretic and analgesic acetaminophen produces delayed
hepatic injury (29, 62). Finally, interactions between DXM and
selective serotonin reuptake inhibitors (SSRIs) or monoamine
oxidase inhibitor (MAOI) might further increase the risk of a
serotoninergic syndrome occurrence (67, 68, 121, 124).
Although widely used and generally considered safe, cases
of antihistamine abuse and dependence have been recorded
(125). These molecules were originally marketed for their
antiallergy properties and are now made available as sleeping
aids. Antihistamines’ toxicity appears to be clinically related
to both central and peripheral acetylcholine antagonism. In
addition, specifically due to multiple potential mechanisms
of action, DPH (e.g., the antihistamine moiety of DH) can
acutely block the cell membrane pump mechanism of central
5-hydroxytryptophane and peripheral noradrenaline neurons,
causing the euphoria reported by some users (Table 1). At high
dosages, and taken together with other drugs (e.g., alcohol,
cannabis, and stimulants), DPH and DH might be used to
achieve a stimulant effect (87, 91, 92, 126, 127). Reported
cases of DPH dependence have resulted from long-term usage
of large doses (often over 1,000 mg/day). Gradual tapering
has been described to alleviate withdrawal symptoms (17,
125). Conversely, promethazine is used in cough syrups for
its antihistaminic, antiemetic, and sedative effects, available
with codeine in common cough suppressants (128); its abuse
potential appears related to its calming and sedating effect
and enhancement of other coingested substances (Table 1).
A recreational use of promethazine mixed with a soft drink
and/or alcohol (“purple drank”) is currently popular among
young people for its euphoric effects and easy accessibility
(19, 20, 129–131). Promethazine has been reported in SUD
clients and is misused as a substitute for another drug or to
increase the effects of inadequate dosing (i.e., to delay the onset
of opioid withdrawal or to potentiate the sedating effect of
benzodiazepines/Z-drugs) (13, 19, 20, 103, 129, 130, 132, 133).
Overdose of promethazine is associated with an antimuscarinic
delirium, agitation, and neuroleptic malignant syndrome (100,
102, 104, 133). Scott et al. (104) recorded a promethazine-
induced delirium treated with physostigmine intravenously,
which reversed both central and peripheral anticholinergic
effects, similarly to a polydrug overdose due to the ingestion
Frontiers in Psychiatry | www.frontiersin.org 8 May 2021 | Volume 12 | Article 657397
Schifano et al. Focus on Over-the-Counter Drugs’ Misuse
of DPH (94). Chlorpheniramine is used as a cheap sleep aid
and/or as an anxiolytic due to its antimuscarinic properties;
its abuse has been related to pleasurable feelings, which
reinforces the repetitive use and the possibility of developing
drug dependence (Table 1). It may, however, be associated with
psychotic symptoms in predisposed individuals [e.g., people
with mental illnesses or individuals concomitantly abusing
other drugs; (42, 43, 114, 115)].
Codeine was reported within the misusing scenario of
codeine-based cough and cold medicines and/or coingested with
other substances, e.g., DXM, DPH, ephedrine, pseudoephedrine,
methyl ephedrine, chlorpheniramine, promethazine, caffeine
(26, 27, 34, 78–80, 100, 114, 134). Codeine is a natural
isomer of methylated morphine and, similarly to DXM, is a
prodrug, requiring metabolic activation by O-demethylation
to morphine by CYP2D6. Thus, codeine-related effects are
associated with CYP2D6 metabolism, e.g., ultrarapid CYP2D6
metabolizers produce an unexpectedly large amount of
morphine, with resulting life-threatening opioid toxicity. Its
recreational use is related to the agonism at mu receptors and
the subjective effects of euphoria, elation, analgesia, and “liking”
(114, 121). Codeine toxicity is characterized by respiratory
depression and extreme somnolence progressing to stupor
or coma (79); in severe overdosage cases, death may occur
(121) (Supplementary Table 1 and Table 1). Idiosyncratic
codeine administration procedures have been recorded, e.g.,
a misuser learned online how the codeine base might be
extracted through a process called cold water extraction
(CWE) to be then injected. Regular use of codeine is described
here together with the development of both tolerance (135)
and dependence (80, 114).
Decongestants, here recorded as being abused, both alone
and with coingestants, were ephedrine and its stereoisomer
pseudoephedrine (78, 79, 106–109, 111, 112), which are
sympathomimetic agents (136, 137) exerting a stimulating
action on both alpha- and beta-adrenergic receptors (136, 137)
(Supplementary Table 1 and Table 1). Indeed, ephedrine has
been reported to obtain weight loss or to enhance athletic
performance; both pseudoephedrine and ephedrine have been
recorded as used illicitly in the production of methamphetamine
(136, 138). The abuse was here associated with high dosage (106–
109) and IV administration (108, 111, 112). Dependence issues
have been recorded (106–109).
LIMITATIONS
One of the difficulties regarding the literature on prescription
drug misuse is both its heterogeneity and the issues in identifying
misusing practices; interpretation was easier for both those cases
reported by healthcare professionals, whose intervention was
needed, National/Regional PoisonData System information (100,
101), etc. According to UNODC, the misuse of medicines is
defined as “the problematic consumption outside of acceptable
medical practice or medical guidelines, when self-medicating at
higher doses and for longer than is advisable, for intoxicating
purposes and when risks and adverse consequences outweigh the
benefit” (8–11). However, levels of terminology variability and
inconsistency to describe the OTC phenomenon were identified
as well; this use was referred to as non-medical use, problem use,
harmful use, recreational use, self-medication, or inappropriate
use, which calls into question whether there is a consensus on
the negative consequences (i.e., problem, harm) of OTC use.
Indeed, some of these terms may not even necessarily refer to the
same issue (8).
CONCLUSIONS
The current systematic review showed that OTC misuse is
an increasingly relevant health issue associated with potential
harms, including drug-related toxicity, addiction, and fatalities.
Nowadays, the CoViD-19 pandemic has likely facilitated the
occurrence of these misusing practices, as more users turned
from street drugs to prescription/OTC products (14, 15). Indeed,
OTC drugs are both widely accessible and perceived because of
their favorable legal status as relatively safe, hence accepted in
a “pill-popping culture” (11). There is the need of both drafting
ad hoc treatment guidelines and planning preventative measures.
These measures should revolve around the implementation of
a range of associated issues, including scheduling amendments,
proper surveillance, enhanced detection of misuse in clinical and
pharmacy practice, and promotion of public health awareness
initiatives (9, 11, 16, 139–141). As an example, due to the recent
rise in opioid abuse and related overdose deaths worldwide,
efforts are focusing on strengthening public health surveillance
and limiting opioid prescribing (142, 143). Specifically, as
codeine-containing products misusing levels might be hampered
by their widespread and easy availability, upscheduling and
pharmacy-based interventions targeting users might limit the
purchase of codeine products without a prescription. The recent
introduction of new OTC combinations with non-opioid agents
may provide a safer alternative to these widely misused products
(144). In the case of the antidiarrheal loperamide, found to be
misused at high dosages and associated with cardiotoxicity, to
support its safe use, the Food and Drug Administration (FDA)
approved changes to the packaging for tablet and capsule forms
limiting each carton to no more than 48mg of loperamide and
requiring the tablets and capsules to be packaged in individual
doses (145). A range of professionals should be involved in
tackling the OTC misusing issues, including (i) physicians,
especially general practitioners (GP), who can help OTCmisusers
in early recognizing a drug-related problem and refer them
to the appropriate service (e.g., mental or addiction services);
they should also take note of rapid increases in the amount of
medication needed or frequent, unscheduled refill requests and
uncovering possible “doctor shopping” practices. Physicians will
continue to have a role in educating users to ensure that they use
medications appropriately, following the prescribed directions,
while being aware of potential interactions with other licit/illicit
drugs (11, 16, 18, 116, 135, 141). Conversely, pharmacists
should be watchful for prescription falsifications or alterations,
being at the frontline in recognizing prescription drug abuse
issues. Moreover, prescription drug monitoring programs could
Frontiers in Psychiatry | www.frontiersin.org 9 May 2021 | Volume 12 | Article 657397
Schifano et al. Focus on Over-the-Counter Drugs’ Misuse
assist healthcare professionals in identifying patients who are
getting prescriptions from multiple sources (11, 13, 16–18, 141,
144, 146). Finally, abuse prevention campaigns might provide
valuable resources on raising awareness and preventing medicine
abuse [https://stopmedicineabuse.org/; (144)].
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